NO20004274L - Protease-activated receptor 4 and its use - Google Patents

Protease-activated receptor 4 and its use

Info

Publication number
NO20004274L
NO20004274L NO20004274A NO20004274A NO20004274L NO 20004274 L NO20004274 L NO 20004274L NO 20004274 A NO20004274 A NO 20004274A NO 20004274 A NO20004274 A NO 20004274A NO 20004274 L NO20004274 L NO 20004274L
Authority
NO
Norway
Prior art keywords
protease
activated receptor
receptor
activated
Prior art date
Application number
NO20004274A
Other languages
Norwegian (no)
Other versions
NO20004274D0 (en
Inventor
Shaun R Coughlin
Mark Kahn
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NO20004274D0 publication Critical patent/NO20004274D0/en
Publication of NO20004274L publication Critical patent/NO20004274L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
NO20004274A 1998-02-27 2000-08-25 Protease-activated receptor 4 and its use NO20004274L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3239798A 1998-02-27 1998-02-27
PCT/US1999/002983 WO1999043809A2 (en) 1998-02-27 1999-02-11 Protease-activated receptor 4 and uses thereof

Publications (2)

Publication Number Publication Date
NO20004274D0 NO20004274D0 (en) 2000-08-25
NO20004274L true NO20004274L (en) 2000-10-13

Family

ID=21864751

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004274A NO20004274L (en) 1998-02-27 2000-08-25 Protease-activated receptor 4 and its use

Country Status (7)

Country Link
EP (1) EP1056854A2 (en)
JP (1) JP2002504369A (en)
KR (1) KR20010041418A (en)
AU (1) AU2672899A (en)
CA (1) CA2321142A1 (en)
NO (1) NO20004274L (en)
WO (1) WO1999043809A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892014A (en) 1996-10-30 1999-04-06 The Regents Of The University Of California DNA encoding a protease-activated receptor 3
US6111075A (en) * 1998-04-01 2000-08-29 Zymogenetics, Inc. Protese-activated receptor PAR4 (ZCHEMR2)
NZ510456A (en) * 1998-09-15 2004-01-30 Univ Melbourne A method of treatment and agents useful for same
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
GB9925005D0 (en) 1999-10-22 1999-12-22 Univ Nottingham The treatment of wounds
AU2001233333A1 (en) * 2000-02-09 2001-08-20 Zymogenetics Inc. Par4 peptides and polypeptides
AU2001238366A1 (en) * 2000-02-17 2001-08-27 The Regents Of The University Of California Methods of modulating protease-activated receptor-4 (par4) activation via cathepsin
WO2001094411A1 (en) * 2000-06-05 2001-12-13 The Regents Of The University Of California Peptides modulating protease activated receptors and methods of using same
US6841354B2 (en) * 2000-12-21 2005-01-11 Philadelphia, Health & Education Corporation Screening assay for anti-thrombotic/anti-platelet activity
US7179887B2 (en) 2001-03-02 2007-02-20 Ortho-Mcneil Pharmaceutical, Inc. Guinea pig proteinase-activated receptor 4 and its activating peptide
WO2004080372A2 (en) * 2003-03-11 2004-09-23 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 4 (par4)
US7790362B2 (en) 2003-07-08 2010-09-07 Accumetrics, Inc. Controlled platelet activation to monitor therapy of ADP antagonists
US20070243632A1 (en) 2003-07-08 2007-10-18 Coller Barry S Methods for measuring platelet reactivity of patients that have received drug eluting stents
US20080299587A1 (en) * 2007-05-03 2008-12-04 Dennis Durbin Methods of measuring inhibition of platelet aggregation by thrombin receptor antagonists
GB2450747A (en) * 2007-07-06 2009-01-07 Univ Sheffield Treatment of sensorineural hearing loss
CN101970456B (en) 2008-01-31 2014-11-26 国立大学法人大阪大学 Tag peptide and its application
ES2968371T3 (en) 2013-10-10 2024-05-09 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as 12-lipoxygenase inhibitors
US11319528B2 (en) 2015-07-13 2022-05-03 University Of Utah Research Foundation Methods of making red blood cells and platelets in vitro and uses thereof
KR102755742B1 (en) 2017-09-11 2025-01-15 모나쉬 유니버시티 Human thrombin receptor PAR4 binding protein
WO2020072471A1 (en) * 2018-10-05 2020-04-09 University Of Utah Research Foundation Methods of making platelets comprising modified receptors and uses thereof
US12618076B2 (en) 2019-10-01 2026-05-05 University Of Utah Research Foundation Methods of engineering platelets for targeting circulating tumor cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686597A (en) * 1995-06-06 1997-11-11 Incyte Pharmaceuticals, Inc. Thrombin receptor homolog
US5892014A (en) * 1996-10-30 1999-04-06 The Regents Of The University Of California DNA encoding a protease-activated receptor 3
WO1998031810A2 (en) * 1997-01-21 1998-07-23 Schering Corporation Mammalian chemokines; receptors; reagents; uses

Also Published As

Publication number Publication date
WO1999043809A3 (en) 1999-10-14
WO1999043809A2 (en) 1999-09-02
KR20010041418A (en) 2001-05-15
JP2002504369A (en) 2002-02-12
AU2672899A (en) 1999-09-15
NO20004274D0 (en) 2000-08-25
CA2321142A1 (en) 1999-09-02
EP1056854A2 (en) 2000-12-06

Similar Documents

Publication Publication Date Title
NO20004274D0 (en) Protease-activated receptor 4 and its use
NO20032753D0 (en) Compound and Use thereof
NL300295I1 (en) 3,3-Diarylpropylamines, their use and preparation
IS4481A (en) Dihydropyramidine and their use
DK1454907T3 (en) Quninazoline and pyridopyrmidine derivatives
IS6411A (en) Kaspasa inhibits and their use
DK0915880T3 (en) Azolotriazines and pyrimidines
DK1003774T3 (en) GnRH antagonists modified at positions 5 and 6
DE69734443D1 (en) OB RECEPTOR AND LIGANDS
NO984354D0 (en) Newspaper and its use
DE69835254D1 (en) Receiving devices and receiving methods
DK0804078T3 (en) Composition and use thereof
NO20006488D0 (en) Composition and application
PT9373T (en) ANATOMICAL PILLOW AND PILLOW
DE69714725D1 (en) PERSONAL ORIENTATION DEVICE
NO20013237D0 (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
DK1068238T3 (en) INTEGRITY UNIT RODIMES AND SUBUNIT THEREOF
DK0903130T3 (en) Improvements in ostomy devices
DE69916694D1 (en) 2-hydroxy-5-methyl-hexan-3-one and 3-hydroxy-5-methyl-hexan-2-one
DK1140952T3 (en) Phosphorus-organic compounds and their use
PT811593E (en) INSECTICID AND ACARICID AGENTS 1,4-DIARY-2-FLUOR-2-BUTENE
NO983556D0 (en) Formulation and application
FI974018L (en) Human 2 integrin subunit
NO981089D0 (en) Epoxy-azetidinones, preparation and use thereof
DE59812220D1 (en) HOLDING AND WEARBAND

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application